First volunteer receives new COVID-19 vaccine

- Advertisement -




The first healthy volunteer has now received a new coronavirus vaccine developed by researchers led by Professor Robin Shattock at Imperial College London.
The phase I trials were funded by UKRI as part of the UKRI/DHSC/NIHR COVID-19 rapid research response.
The study will be the first time the vaccine has been trialled in humans and will test whether it is well-tolerated and produces an effective immune response against COVID-19.



It will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases.
The vaccine has undergone rigorous pre-clinical safety tests and in animal studies it has been shown to be safe and produced encouraging signs of an effective immune response.



- Advertisement -

Professor Fiona Watt, Executive Chair of the Medical Research Council, which helped fund the trial, said: “In less than six months from the first reports of the emergence of COVID-19 in China, and with support from UKRI and DHSC, we now have two promising UK vaccines in human trials. This astonishingly fast vaccine development – compared to the years it normally takes – is a result of the remarkably hard and collaborative work of the scientists, trialists and regulators. These human trials will contribute to global efforts to find a vaccine, which is our best hope for preventing COVID-19 and enabling life to return to normal.”

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.